Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology

Prior treatment

• Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).
• Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.

Other illness

• Patient with known allergy to citrate or (cyclo)-Taurolidine.

Other

• Patient with retinoblastoma.
• Allografted patient.
• Patient with a life expectancy of less than 6 months.
• Patient refusing to participate in the protocol.
• Patient with an external femoral catheter.
• Patient with a PICCLINE-type peripheral venous inserted central catheter.
• Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.
• Patient under guardianship and curatorship.

• Patient less than or equal to 21 years of age at inclusion.
• Patient for whom a central catheter is planned to be inserted\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal).
• Patient treated for a cancer.
• Patient with regular follow-up in the inclusion center.
• Informed consent signed by the patient if adult or by legal representatives if minor.
• Patient benefiting from a social security coverage.
• Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.